Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Fruquintinib Plus FOLFIRI as Second-line Treatment in RAS-mutated Metastatic Colorectal Cancer

NCT05842525 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT05842525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05842525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Fruquintinib Plus FOLFIRI as Second-line Treatment in RAS-mutated Metastatic Colorectal Cancer
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2023
Completion date
December 30, 2024
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer